The federal hiring freeze implemented by the Trump Administration adds another challenge to the ongoing struggle by FDA’s Center for Drug Evaluation & Research to recruit and retain qualified individuals to fill both open executive leadership positions and vacancies within its drug review teams.
While CDER’s recruitment challenges are longstanding and well-publicized by the 21st Century Cures legislative discussion, the Jan. 23
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?